C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis
- PMID: 24223894
- PMCID: PMC3817069
- DOI: 10.1371/journal.pone.0079137
C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis
Abstract
Background: c-Met has been recognized as an important therapeutic target in gastric cancer, but the prognostic property of the c-Met status is still unclear. We aimed to characterize the prognostic effect of c-Met by systematic review and meta-analysis.
Methods: We identified 15 studies assessing survival in gastric cancer by c-Met status. Effect measure of interest was hazard ratio (HR) for survival. Meta-regression was performed to estimate the relationship between HR and disease stage. Random-effects meta-analyses were used to account for heterogeneity.
Results: 15 eligible studies provided outcome data stratified by c-Met status in 2210 patients. Meta-analysis of the HRs indicated a significantly poorer Os in patients with high c-Met expression (average HR=2.112, 95%CI: 1.622-2.748). Subgroup analysis showed the prognostic effect of c-Met was identical in protein-level and gene-level based methodology. The same effect was also seen in Asian and Western ethnicity subgroup analysis. Meta-regression showed HR was not associated with disease stage.
Conclusions: Patients with tumors that harbor high c-Met expression are more likely to have a worse Os, with this prognostic effect independent of disease stage. c-Met status should be evaluated in clinical prognosis.
Conflict of interest statement
Figures





Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Chemotherapy for advanced gastric cancer.Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4. Cochrane Database Syst Rev. 2017. PMID: 28850174 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
Cited by
-
Remodeling of the pulmonary artery induced by metastatic gastric carcinoma: a histopathological analysis of 51 autopsy cases.BMC Cancer. 2014 Jan 10;14:14. doi: 10.1186/1471-2407-14-14. BMC Cancer. 2014. PMID: 24410891 Free PMC article.
-
Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy.Genes Cancer. 2016 Jan;7(1-2):27-35. doi: 10.18632/genesandcancer.96. Genes Cancer. 2016. PMID: 27014419 Free PMC article.
-
Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis.Oncotarget. 2017 Aug 22;8(42):73098-73104. doi: 10.18632/oncotarget.20392. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069852 Free PMC article.
-
Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review.Oncotarget. 2017 Aug 9;8(52):90351-90357. doi: 10.18632/oncotarget.20087. eCollection 2017 Oct 27. Oncotarget. 2017. PMID: 29163834 Free PMC article.
-
MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines.J Cancer Res Clin Oncol. 2021 Jan;147(1):167-175. doi: 10.1007/s00432-020-03395-4. Epub 2020 Sep 26. J Cancer Res Clin Oncol. 2021. PMID: 32980960 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous